Melbourne, Australia, 05 May 2020: OccuRx, a biotechnology company focused on improving lives by developing innovative precision treatments for inflammatory and fibrotic diseases today announces the initiation of the multiple ascending dose (MAD) phase for its lead candidate OCX-063.
Following the successful progress of the SAD portion of the Phase I study being conducted at Nucleus Network in Melbourne, OccuRx will commence the multiple ascending doses (MAD) phase for its lead candidate OCX063.
OccuRx are dedicated to identifying and validating novel targets that treat and prevent fibrosis that lead to disease progression and end organ failure.
The Phase I study is a randomized, double blind, placebo-controlled, dose-escalating study of the safety, tolerability, food effect and pharmacokinetics of single and repeat doses of OCX063; OccuRx’s lead drug candidate, administered orally to healthy volunteers.
OCX063, the drug molecule being tested, is being developed as a first-in-class oral therapy for the treatment for both kidney and ocular diseases. OCX063, is a small molecule drug with the potential to prevent the growth of new and abnormal blood vessels and reduce inflammation. “We’re excited to move forward with the MAD portion as part of our Phase I clinical program for OCX063 and look forward to reviewing the safety and tolerability readouts on completion of the study, which is anticipated later this year” said Professor Darren Kelly, Executive Chair of OccuRx.
